p53-mutated tumors often exhibit increased resistance to standard chemotherapy and enhanced metastatic potential. Here we demonstrate that inhibition of dihydroorotate dehydrogenase (DHODH), a key enzyme of the de novo pyrimidine synthesis pathway, effectively decreases proliferation of cancer cells via induction of replication and ribosomal stress in a p53- and checkpoint kinase 1 (Chk1)-dependent manner. Mechanistically, a block in replication and ribosomal biogenesis result in p53 activation paralleled by accumulation of replication forks that activate the ataxia telangiectasia and Rad3-related kinase/Chk1 pathway, both of which lead to cell cycle arrest. Since in the absence of functional p53 the cell cycle arrest fully depends on Chk1, combined DHODH/Chk1 inhibition in p53-dysfunctional cancer cells induces aberrant cell cycle re-entry and erroneous mitosis, resulting in massive cell death. Combined DHODH/Chk1 inhibition effectively suppresses p53-mutated tumors and their metastasis, and therefore presents a promising therapeutic strategy for p53-mutated cancers.

Academy of Geriatric Cancer Research Department of Oncology Odense University Hospital 5000 Odense Denmark

Department of Cancer and Inflammation Research Institute of Molecular Medicine University of Southern Denmark 5000 Odense Denmark

Faculty of Science Charles University Prague Czech Republic

Laboratory of Molecular Therapy Institute of Biotechnology Czech Academy of Sciences Prague West 252 50 Czech Republic

School of Medical Science Griffith University Southport QLD 4222 Australia

Zobrazit více v PubMed

Schrepfer E, Scorrano L. Mitofusins, from mitochondria to metabolism. Mol. Cell. 2016;61:683–694. doi: 10.1016/j.molcel.2016.02.022. PubMed DOI

Evans DR, Guy HI. Mammalian pyrimidine biosynthesis: fresh insights into an ancient pathway. J. Biol. Chem. 2004;279:33035–33038. doi: 10.1074/jbc.R400007200. PubMed DOI

Khutornenko AA, et al. Pyrimidine biosynthesis links mitochondrial respiration to the p53 pathway. Proc. Natl. Acad. Sci. USA. 2010;107:12828–12833. doi: 10.1073/pnas.0910885107. PubMed DOI PMC

Jones ME. Pyrimidine nucleotide biosynthesis in animals: genes, enzymes, and regulation of UMP biosynthesis. Annu. Rev. Biochem. 1980;49:253–279. doi: 10.1146/annurev.bi.49.070180.001345. PubMed DOI

Bester AC, et al. Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell. 2011;145:435–446. doi: 10.1016/j.cell.2011.03.044. PubMed DOI PMC

Mathur D, et al. PTEN regulates glutamine flux to pyrimidine synthesis and sensitivity to dihydroorotate dehydrogenase inhibition. Cancer Discov. 2017;7:380–390. doi: 10.1158/2159-8290.CD-16-0612. PubMed DOI PMC

Liu L, et al. Inactivation/deficiency of DHODH induces cell cycle arrest and programed cell death in melanoma. Oncotarget. 2017;8:112354–112370. PubMed PMC

Brown KK, Spinelli JB, Asara JM, Toker A. Adaptive reprogramming of de novo pyrimidine synthesis is a metabolic vulnerability in triple-negative breast cancer. Cancer Discov. 2017;7:391–399. doi: 10.1158/2159-8290.CD-16-0611. PubMed DOI PMC

Sykes DB, et al. Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia. Cell. 2016;167:171–186 e115. doi: 10.1016/j.cell.2016.08.057. PubMed DOI PMC

Zhang Y, Lu H. Signaling to p53: ribosomal proteins find their way. Cancer Cell. 2009;16:369–377. doi: 10.1016/j.ccr.2009.09.024. PubMed DOI PMC

Dai MS, Lu H. Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J. Biol. Chem. 2004;279:44475–44482. doi: 10.1074/jbc.M403722200. PubMed DOI

Bhat KP, Itahana K, Jin A, Zhang Y. Essential role of ribosomal protein L11 in mediating growth inhibition-induced p53 activation. EMBO J. 2004;23:2402–2412. doi: 10.1038/sj.emboj.7600247. PubMed DOI PMC

Zhang Y, et al. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol. Cell Biol. 2003;23:8902–8912. doi: 10.1128/MCB.23.23.8902-8912.2003. PubMed DOI PMC

Soussi T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann. NY Acad. Sci. 2000;910:121–137. doi: 10.1111/j.1749-6632.2000.tb06705.x. PubMed DOI

Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 2003;3:421–429. doi: 10.1016/S1535-6108(03)00110-7. PubMed DOI

Xu YJ, Leffak M. ATRIP from TopBP1 to ATR-in vitro activation of a DNA damage checkpoint. Proc. Natl. Acad. Sci. USA. 2010;107:13561–13562. doi: 10.1073/pnas.1008909107. PubMed DOI PMC

Xiao Z, et al. Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. J. Biol. Chem. 2003;278:21767–21773. doi: 10.1074/jbc.M300229200. PubMed DOI

Huang X, Tran T, Zhang L, Hatcher R, Zhang P. DNA damage-induced mitotic catastrophe is mediated by the Chk1-dependent mitotic exit DNA damage checkpoint. Proc. Natl. Acad. Sci. USA. 2005;102:1065–1070. doi: 10.1073/pnas.0409130102. PubMed DOI PMC

Feijoo C, et al. Activation of mammalian Chk1 during DNA replication arrest: a role for Chk1 in the intra-S phase checkpoint monitoring replication origin firing. J. Cell Biol. 2001;154:913–923. doi: 10.1083/jcb.200104099. PubMed DOI PMC

Bajzikova M, et al. Reactivation of dihydroorotate dehydrogenase by respiration restores tumor growth of mitochondrial DNA-depleted cancer cells. Cell Metab. 2019;29:399–416. doi: 10.1016/j.cmet.2018.10.014. PubMed DOI PMC

Kotsantis P, Petermann E, Boulton SJ. Mechanisms of oncogene-induced replication stress: jigsaw falling into place. Cancer Discov. 2018;8:537–555. doi: 10.1158/2159-8290.CD-17-1461. PubMed DOI PMC

Choi JH, et al. Reconstitution of RPA-covered single-stranded DNA-activated ATR-Chk1 signaling. Proc. Natl. Acad. Sci. USA. 2010;107:13660–13665. doi: 10.1073/pnas.1007856107. PubMed DOI PMC

Salim D, et al. DNA replication stress restricts ribosomal DNA copy number. PLoS Genet. 2017;13:e1007006. doi: 10.1371/journal.pgen.1007006. PubMed DOI PMC

Burger K, et al. Chemotherapeutic drugs inhibit ribosome biogenesis at various levels. J. Biol. Chem. 2010;285:12416–12425. doi: 10.1074/jbc.M109.074211. PubMed DOI PMC

Fumagalli S, et al. Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction. Nat. Cell Biol. 2009;11:501–508. doi: 10.1038/ncb1858. PubMed DOI PMC

Bursac S, et al. Mutual protection of ribosomal proteins L5 and L11 from degradation is essential for p53 activation upon ribosomal biogenesis stress. Proc. Natl. Acad. Sci. USA. 2012;109:20467–20472. doi: 10.1073/pnas.1218535109. PubMed DOI PMC

Vakifahmetoglu H, Olsson M, Zhivotovsky B. Death through a tragedy: mitotic catastrophe. Cell Death Differ. 2008;15:1153–1162. doi: 10.1038/cdd.2008.47. PubMed DOI

Xu D, Bai J, Duan Q, Costa M, Dai W. Covalent modifications of histones during mitosis and meiosis. Cell Cycle. 2009;8:3688–3694. doi: 10.4161/cc.8.22.9908. PubMed DOI

Turinetto V, Vitale E, Giachino C. Senescence in human mesenchymal stem cells: functional changes and implications in stem cell-based therapy. Int. J. Mol. Sci. 2016;17:E1164. doi: 10.3390/ijms17071164. PubMed DOI PMC

Huang M, Graves LM. De novo synthesis of pyrimidine nucleotides; emerging interfaces with signal transduction pathways. Cell. Mol. Life Sci. 2003;60:321–336. doi: 10.1007/s000180300027. PubMed DOI PMC

Fairbanks LD, Bofill M, Ruckemann K, Simmonds HA. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J. Biol. Chem. 1995;270:29682–29689. doi: 10.1074/jbc.270.50.29690. PubMed DOI

Loffler M, Fairbanks LD, Zameitat E, Marinaki AM, Simmonds HA. Pyrimidine pathways in health and disease. Trends Mol. Med. 2005;11:430–437. doi: 10.1016/j.molmed.2005.07.003. PubMed DOI

Christian Sven, Merz Claudia, Evans Laura, Gradl Stefan, Seidel Henrik, Friberg Anders, Eheim Ashley, Lejeune Pascale, Brzezinka Krzysztof, Zimmermann Katja, Ferrara Steven, Meyer Hanna, Lesche Ralf, Stoeckigt Detlef, Bauser Marcus, Haegebarth Andrea, Sykes David B, Scadden David T, Losman Julie-Aurore, Janzer Andreas. The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies. Leukemia. 2019;33(10):2403–2415. doi: 10.1038/s41375-019-0461-5. PubMed DOI

Dorasamy MS, Choudhary B, Nellore K, Subramanya H, Wong PF. Dihydroorotate dehydrogenase inhibitors yarget c-Myc and arrest melanoma, myeloma and lymphoma cells at S-phase. J. Cancer. 2017;8:3086–3098. doi: 10.7150/jca.14835. PubMed DOI PMC

Bebenek K, Kunkel TA. Frameshift errors initiated by nucleotide misincorporation. Proc. Natl Acad. Sci. USA. 1990;87:4946–4950. doi: 10.1073/pnas.87.13.4946. PubMed DOI PMC

Reichard P. Interactions between deoxyribonucleotide and DNA synthesis. Annu. Rev. Biochem. 1988;57:349–374. doi: 10.1146/annurev.bi.57.070188.002025. PubMed DOI

Mohamad Fairus AK, Choudhary B, Hosahalli S, Kavitha N, Shatrah O. Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells. Biochimie. 2017;135:154–163. doi: 10.1016/j.biochi.2017.02.003. PubMed DOI

Ladds M, et al. A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage. Nat. Commun. 2018;9:1107. doi: 10.1038/s41467-018-03441-3. PubMed DOI PMC

Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N. Engl. J. Med. 2004;350:2167–2179. doi: 10.1056/NEJMra032906. PubMed DOI

Palmer AMTeriflunomide. an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis. Curr. Opin. Invest. Drugs. 2010;11:1313–1323. PubMed

Arnould S, et al. Checkpoint kinase 1 inhibition sensitises transformed cells to dihydroorotate dehydrogenase inhibition. Oncotarget. 2017;8:95206–95222. doi: 10.18632/oncotarget.19199. PubMed DOI PMC

Stiff T, et al. ATR-dependent phosphorylation and activation of ATM in response to UV treatment or replication fork stalling. EMBO J. 2006;25:5775–5782. doi: 10.1038/sj.emboj.7601446. PubMed DOI PMC

Velichko AK, et al. Hypoosmotic stress induces R loop formation in nucleoli and ATR/ATM-dependent silencing of nucleolar transcription. Nucleic Acids Res. 2019;47:6811–6825. doi: 10.1093/nar/gkz436. PubMed DOI PMC

White RM, et al. DHODH modulates transcriptional elongation in the neural crest and melanoma. Nature. 2011;471:518–522. doi: 10.1038/nature09882. PubMed DOI PMC

Boisvert FM, van Koningsbruggen S, Navascues J, Lamond AI. The multifunctional nucleolus. Nat. Rev. Mol. Cell. Biol. 2007;8:574–585. doi: 10.1038/nrm2184. PubMed DOI

Marechal V, Elenbaas B, Piette J, Nicolas JC, Levine AJ. The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes. Mol. Cell Biol. 1994;14:7414–7420. doi: 10.1128/MCB.14.11.7414. PubMed DOI PMC

Bartucci M, et al. Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. Cell Death Differ. 2012;19:768–778. doi: 10.1038/cdd.2011.170. PubMed DOI PMC

Laquente B, et al. A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. BMC Cancer. 2017;17:137. doi: 10.1186/s12885-017-3131-x. PubMed DOI PMC

Syljuasen RG, et al. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol. Cell Biol. 2005;25:3553–3562. doi: 10.1128/MCB.25.9.3553-3562.2005. PubMed DOI PMC

Demaria M, et al. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discov. 2017;7:165–176. doi: 10.1158/2159-8290.CD-16-0241. PubMed DOI PMC

Sharma P, Gangopadhyay D, Mishra PC, Mishra H, Singh RK. Detection of in vitro metabolite formation of leflunomide: A Fluorescence Dynamics and Electronic Structure Study. J. Med. Chem. 2016;59:3418–3426. doi: 10.1021/acs.jmedchem.6b00088. PubMed DOI

Pulaski, B. A. & Ostrand-Rosenberg, S. Mouse 4T1 breast tumor model. Curr. Protoc. Immunol. Chapter 20, Unit 20.2 (2001). PubMed

Dimri GP, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA. 1995;92:9363–9367. doi: 10.1073/pnas.92.20.9363. PubMed DOI PMC

Shalem O, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343:84–87. doi: 10.1126/science.1247005. PubMed DOI PMC

Blecha J, et al. Antioxidant defense in quiescent cells determines selectivity of electron transport chain inhibition-induced cell death. Free Radic. Biol. Med. 2017;112:253–266. doi: 10.1016/j.freeradbiomed.2017.07.033. PubMed DOI

Yin S, Kabashima T, Zhu Q, Shibata T, Kai M. Fluorescence assay of dihydroorotate dehydrogenase that may become a cancer biomarker. Sci. Rep. 2017;7:40670. doi: 10.1038/srep40670. PubMed DOI PMC